New hope for tough bladder cancers: trial tests combo therapy
NCT ID NCT07424287
Summary
This study is for people with a high-risk form of bladder cancer that has returned after standard BCG immunotherapy. It will compare a new combination treatment (SHR-1501 plus BCG) against standard chemotherapy drugs chosen by the doctor. The goal is to see if the new combination is better at keeping the cancer from coming back and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.